跳转至内容
Merck
所有图片(1)

Key Documents

更多文件

Y0000421

司他夫定

European Pharmacopoeia (EP) Reference Standard

别名:

2′,3′-二脱氢-3′-脱氧胸苷, Stavudine

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C10H12N2O4
CAS号:
3056-17-5
分子量:
224.21
MDL號碼:
MFCD00132921
分類程式碼代碼:
41116107
PubChem物質ID:
329830945
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

stavudine

製造商／商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O

InChI

1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

InChI 密鑰

XNKLLVCARDGLGL-JGVFFNPUSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Stavudine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 2

閃點（°F）

Not applicable

閃點（°C）

Not applicable

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

A P Lea et al.
Drugs, 51(5), 846-864 (1996-05-01)
Stavudine is a nucleoside analogue which undergoes intracellular phosphorylation to its active metabolite, stavudine-5'-triphosphate. At clinically relevant concentrations, the active metabolite restricts HIV replication by inhibiting the inclusion of thymidine-5'-triphosphate into proviral DNA by HIV reverse transcriptase, and/or by causing
Dam Anh Tran et al.
Sexually transmitted infections, 90(7), 538-544 (2014-03-13)
This study examines the proportions and causes of virological failure after one year of antiretroviral therapy (ART) among people living with HIV (PLHIV) in Vietnam. It also evaluates the positive predictive value (PPV) of immunological criteria to detect treatment failure.
R L Murphy
Antiviral therapy, 3 Suppl 4, 69-73 (2000-03-21)
Initial studies of multiple-agent antiretroviral combinations including the thymidine nucleoside analogue reverse transcriptase inhibitor (RTI) stavudine (2',3'-didehydro-2',3'-dideoxythymidine; D4T) have shown potent anti-HIV effects in both treatment-naive and -experienced patients. A number of ongoing randomized comparative trials are assessing stavudine-based multiple
Nilza Nascimento Guimarães et al.
Expert opinion on drug safety, 9(5), 771-781 (2010-04-10)
The nucleoside reverse transcriptase inhibitors (NRTIs) are used in antiretroviral therapy worldwide for the treatment of HIV infections. These drugs act by blocking reverse transcriptase enzyme activity, causing pro-viral DNA chain termination. As a consequence, NRTIs could cause genomic instability
G Skowron
The Journal of infectious diseases, 171 Suppl 2, S113-S117 (1995-03-01)
Data on the biologic effects and safety of stavudine in patients with AIDS and AIDS-related complex represent results of two phase I trials (n = 84), another phase I study of patients with hematologic intolerance to zidovudine (n = 23)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门